Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial
Karim Fizazi, Pablo González Mella, Daniel Castellano, Jose N. Minatta, Arash Rezazadeh Kalebasty, David Shaffer, Juan C. Vázquez Limón, Héctor M. Sánchez López, Andrew J. Armstrong, Lisa Horvath, Diogo A. Bastos, Neha P. Amin, Jia Li, Keziban Unsal-Kacmaz, Margitta Retz, Fred Saad, Daniel P. Petrylak, Russell K. Pachynski
Dive into the research topics of 'Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial'. Together they form a unique fingerprint.